Vera Clinic, internationally recognised as a leading centre of innovation in hair restoration surgery, has released the full ...

MeiraGTx Holdings (NASDAQ:MGTX) is one of the best growth stocks under $10 to invest in. On April 16, MeiraGTx Holdings entered into an asset purchase agreement with Johnson & Johnson to reacquire all ...

The big five hyperscalers plan to spend a total of more than $700 billion on artificial intelligence (AI) infrastructure this ...

In a significant step towards strengthening surveillance and rapid response to vector-borne diseases, the health & family welfare (H&FW) department has established a dedicated state control room under ...

The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...

Supported by the CHORD trial, this AAV vector-based therapy delivers a working copy of the OTOF gene and restores otoferlin ...

Developed by American Biotechnology company Regeneron, Otarmeni has been approved for the treatment of pediatric and adult ...

Maker says Otarmeni will be offered for free in the U.S.

Three Philadelphia scientists won a $3 million Breakthrough Prize for developing the first FDA-approved gene therapy for a genetic disease, prize sponsors announced Saturday. Their work created a ...

Neuronal specification, expansion and differentiation are tightly regulated by the concerted actions of transcription and chromatin modifying factors that are recruited to regulatory elements in the ...

Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...